Unsere Publikationen auf einen Blick.
Veröffentlichungen
Unsere wissenschaftlichen Publikationen
Emrusolmin (anle138b) ist ein innovativer Oligomer-Modulator, der das Potenzial hat, den Verlauf neurodegenerativer Erkrankungen wie Multiple Systematrophie zu beeinflussen. Detaillierte Informationen zur Wirkungsweise und den vielversprechenden Studien-Ergebnissen finden Sie hier.
Die SAA-Technologie, auch als RT-QuIC bezeichnet, ermöglicht die hochsensitive und spezifische Detektion fehlgefalteter Proteine wie alpha-Synuclein und Prionen in biologischen Proben. Diese Methode bietet vielversprechende Ansätze für die frühzeitige Diagnose und Überwachung neurodegenerativer Erkrankungen. Lesen Sie hier mehr dazu.
Unsere Forschung an PET-Tracern zielt darauf ab, pathologische Proteinablagerungen wie alpha-Synuclein sichtbar zu machen, um neurodegenerative Erkrankungen besser diagnostizieren und deren Fortschreiten überwachen zu können. Mehr dazu erfahren Sie in unseren Publikationen.
Emrusolmin (anle138b)
NATURE COMMUNICATIONS
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils.
THE LANCET – eBioMedicine
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial.
Acta Neuropathologica
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.
Acta Neuropathologica
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.
Acta Neuropathologica
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.
ACS Chemical Neuroscience
Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.
EMBO Molecular Medicine
The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.
Movement Disorders
Anle138b Modulates α-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.
Acta Neuropathologica
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.
Alzheimer’s Research & Therapy
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.
Unser Ziel ist es, ausgehend von den molekularen Grundlagen, neuartige Therapeutika zu entwickeln.
SAA / RT-QuIC
Acta Neuropathologica
A quantitative Lewy‑fold‑specific alpha‑synuclein seed amplification assay as a progression marker for Parkinson’s disease.
Acta Neuropathologica Communications
Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.
Journal of Neuropathology & Experimental Neurology
Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.
FEBS Open Bio
Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.
Schnellere und präzisere Diagnosen
durch PD DETECT
SAA:
Die Zukunft der Protein-Diagnostik
PET tracer development
European Journal of Nuclear Medicine and Molecular Imaging
[¹¹C]MODAG-001-towards a PET tracer targeting α-synuclein aggregates.
ChemMedChem
¹¹C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to α-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.